Volume : 11, Issue : 03, March – 2024
Title:
THE LINK BETWEEN HORMONAL CONTRACEPTIVES AND BREAST CANCER RISK: A SYSTEMATIC REVIEW
Authors :
Fatimah Hussain Alkhamis , Latifah Khalid Alnami , Maryam Hussain Alkhalifah , Alzahra Bader Almughlliq , Enas Saleh Alashtaf , Sara Saleh Alkodae , Fatimah adel alsaad , Noura abdulkhaliq alawad
Abstract :
Objectives: This systematic review aims to investigate the association between hormonal contraceptives (HC) and breast cancer (BC) risk. Methods: A comprehensive search of relevant databases was conducted to identify studies that met the inclusion criteria. PubMed, MEDLINE, and Embase were systematically searched for relevant literature. Rayyan QRCI was employed throughout this comprehensive process. Results: Our results included eight studies with a total of 14,336,867 women. The eight studies included women that used variable HC and four studies did not specify the types of HC. Six studies demonstrated that HC usage was a significant risk factor for the development of BC. Early use before the age of 20 is associated with the highest risk of BC and longer duration of HC use significantly increases the risk of BC. Interestingly, one study found that HC use is not linked to BC usage and another study found that the use of HC is a protective factor against the development of BC. Conclusion: Many studies have indicated a possible risk of BC, despite the fact that hormones offer an effective method of birth control. It is important to weigh the advantages of using HC against the dangers of BC. It is imperative that those using HC are made aware of the importance of BC self-examination and how to conduct it correctly. Research indicates that considering non-hormonal, long-acting, or reversible contraceptives should be carefully considered as alternate forms of birth control.
Keywords: Hormonal contraceptives; Breast cancer; Risk factors; Systematic review.
Cite This Article:
Please cite this article in press Fatimah Hussain Alkhamis et al., The Link Between Hormonal Contraceptives And Breast Cancer Risk: A Systematic Review., Indo Am. J. P. Sci, 2024; 11 (03).
Number of Downloads : 10
References:
1. Beaber EF, Buist DS, Barlow WE, et al. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Res. 2014;74(15):4078-4089. doi:10.1158/0008-5472.CAN-13-3406
2. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347(9017):1713-1727. doi:10.1016/S0140-6736(96)90806-5
3. Marchbanks PA, McDonald JA, Wilson HG, et al. The NICHD Women’s Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol. 2002;12(4):213-221. doi:10.1016/S1047-2797(01)00282-2
4. Romieu I, Berlin JA, Colditz G, et al. Oral contraceptives and breast cancer. Review and meta-analysis. Cancer. 1990;66(10):2253-2263. doi:10.1002/1097-0142(19901115)66:10<2253::AID-CNCR2820661023>3.0.CO;2-9
5. Hunter DJ, Colditz GA, Hankinson SE, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2496-2502. doi:10.1158/1055-9965.EPI-10-0432
6. Althuis MD, Brogan DD, Coates RJ, et al. Breast cancers among very young premenopausal women (United States). Cancer Causes Control. 2003;14(2):151-160. doi:10.1023/A:1023042304637
7. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception. 1996;54(3 Suppl):1S-106S.
8. Li CI, Beaber EF, Tang MT, et al. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res. 2012;72(8):2028-2035. doi:10.1158/0008-5472.CAN-11-4064
9. Dumeaux V, Ursin G, Hofvind S, et al. Hormone replacement therapy, body mass, and mammographic density: a prospective study. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1062-1069. doi:10.1158/1055-9965.EPI-04-0801
10. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. International journal of surgery. 2021 Apr 1;88:105906.
11. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Systematic reviews. 2016 Dec;5:1-0.
12. Munn Z, Aromataris E, Tufanaru C, Stern C, Porritt K, Farrow J, Lockwood C, Stephenson M, Moola S, Lizarondo L, McArthur A. The development of software to support multiple systematic review types: the Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI). JBI evidence implementation. 2019 Mar 1;17(1):36-43.
13. Alsammarraie AZ, Mubarak AA, Alnuaimi AS, Kamal AM. Association of oral contraceptives use with breast cancer and hormone receptor status in Iraqi women. Open Access Macedonian Journal of Medical Sciences. 2020 Dec 10;8(B):1244-50.
14. Ostroot MK, Heslin K, Kram JJ, Tjoe JA, Dorton B. Breast cancer recurrence risk after hormonal contraceptive use in survivors of reproductive age. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2021 Mar 1;258:174-8.
15. Hultstrand JN, Gemzell-Danielsson K, Kallner HK, Lindman H, Wikman P, Sundström-Poromaa I. Hormonal contraception and risk of breast cancer and breast cancer in situ among Swedish women 15–34 years of age: a nationwide register-based study. The Lancet Regional Health–Europe. 2022 Oct 1;21.
16. Solikhah S , Monthida S , Ratu M , Wulan R , Rochana R. Hormonal contraceptive use related to breast cancer among women in Indonesia: a nationwide study. International Journal of Public Health Science (IJPHS) Vol. 11, No. 3, September 2022, pp. 779~784.
17. Dwi Andayani SR, Aprillia R, Ratnawati M. The Correlation of Duration of Hormonal Contraception with the Case of Breast Cancer at RSUD Jombang. Indian Journal of Public Health Research & Development. 2019 Aug 1;10(8).
18. Yermi Y, Adam A, Ningsih ES, Iriani R, Surya S, Rukayah S. The Effect of Using Hormonal Contraception on the Incidence of Breast Cancer. International Journal of Health Sciences. 2023 Jun 30;1(2):173-80.
19. Hisham Mohammed M, Abbas Oleiwi S, Abdulrazzaq Assi M. Assessment of Hormonal Changes Due to Contraception Pills as Risk Factor of Breast Cancer at Najaf city. Iranian Journal of Breast Diseases. 2022 Sep 10;15(3):18-28.
20. Putri NN, Wulaningtyas ES. The Relationship between Hormonal Contraceptive Use and The Risk of Breast Cancer Among Women in Kediri, East Java. InThe International Conference on Public Health Proceeding 2021 Nov 18 (Vol. 6, No. 01, pp. 816-820).
21. Cibula, D.; Gompel, A.; Mueck, A.O.; La Vecchia, C.; Hannaford, P.C.; Skouby, S.O.; Zikan, M.; Dusek, L. Hormonal Contraception and Risk of Cancer. Hum. Reprod. Update 2010, 16, 631–650.
22. Heting, M.; Wenping, L.; Yanan, W.; Dongni, Z.; Xiaoqing, W.; Zhli, Z. Levonorgestrel Intrauterine System and Breast Cancer Risk: An Updated Systematic Review and Meta-Analysis of Observational Studies. Heliyon 2023, 9, e14733.
23. Hardman, S.M.R.; Gebbie, A.E. The Contraception Needs of the Perimenopausal Woman. Best Pract. Res. Clin. Obstet. Gynaecol. 2014, 28, 903–915.
24. Curtis, K.M.; Zapata, L.B.; Pagano, H.P.; Nguyen, A.; Reeves, J.; Whiteman, M.K. Removing Unnecessary Medical Barriers to Contraception: Celebrating a Decade of the U.S. Medical Eligibility Criteria for Contraceptive Use. J. Womens Health 2021, 30, 293–300.
25. Kanadys, W.; Barańska, A.; Malm, M.; Błaszczuk, A.; Polz-Dacewicz, M.; Janiszewska, M.; Jędrych, M. Use of Oral Contraceptives as a Potential Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis of Case-Control Studies Up to 2010. Int. J. Environ. Res. Public Health 2021, 18, 4638.
26. Aparicio, T.; Baer, R.; Gautier, J. DNA Double-Strand Break Repair Pathway Choice and Cancer. DNA Repair 2014, 19, 169–175.
27. Nagykálnai, T.; Landherr, L. Oral contraception and the risk of breast cancer. Review of the literature. Magy. Onkol. 2018, 62, 258–263.
28. Mohamed AM, Alshammari FK, Alotayfi RF, Alenazi KH, Alruwaili AM. The relationship between hormonal contraception and breast cancer. Archives of Pharmacy Practice. 2020;11(4-2020):124-9.
29. Utami DA, Murti B, Budihastuti UR. Oral and Injection Hormonal Contraceptives Uptake and Their Risk to Breast Cancer: A Meta-Analysis. Journal of Maternal and Child Health. 2022 May 16;7(3):346-58.
30. Satish, S.; Moore, J.F.; Littlefield, J.M.; Bishop, I.J.; Rojas, K.E. Re-Evaluating the Association Between Hormonal Contraception and Breast Cancer Risk. Breast Cancer Targets Ther. 2023, 15, 227–235.
31. Pragout, D.; Laurence, V.; Baffet, H.; Raccah-Tebeka, B.; Rousset-Jablonski, C. Contraception et Cancer. RPC Contraception CNGOF. Gynécologie Obs. Fertil. Sénologie 2018, 46, 834–844.
32. Chabbert-Buffet, N.; Marret, H.; Agostini, A.; Cardinale, C.; Hamdaoui, N.; Hassoun, D.; Jonville-Bera, A.P.; Lambert, M.; Linet, T.; Pienkowski, C.; et al. Clinical Practice Guidelines for Contraception by the French National College of Gynecologists and Obstetricians (CNGOF). J. Gynecol. Obstet. Hum. Reprod. 2019, 48, 441–454.
33. World Health Organization. Selected Practice Recommendations for Contraceptive Use, 3rd ed.; WHO Guidelines Approved by the Guidelines Review Committee; World Health Organization: Geneva, Switzerland, 2016; ISBN 978-92-4-156540-0.
34. Bonfiglio, R.; Di Pietro, M.L. The Impact of Oral Contraceptive Use on Breast Cancer Risk: State of the Art and Future Perspectives in the Era of 4P Medicine. Semin. Cancer Biol. 2021, 72, 11–18.